ASCO26: Sara Tolaney, MD, MPH, ASCENT-03 - Top-Institutions - MDSpire

ASCO26: Sara Tolaney, MD, MPH, ASCENT-03

Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.

July 1, 2026

Dana-Farber

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

Dana-Farber Cancer Institute

Boston, MA
Key Differentiators
- Oncology
#2

University of Chicago

Chicago, IL
Key Differentiators
- Oncology
#3

Harvard

Cambridge, MA
Key Differentiators
- Oncology
#4

Dana-Farber/Brigham and Women’s Cancer Center

Boston, MA
Key Differentiators
- Oncology
#5

Memorial Sloan Kettering Cancer Center

New York, NY
Key Differentiators
- Oncology